ACADIA Pharmaceuticals Inc

28 de ago. de 2026, 20:07 UTC

ACADIA Pharmaceuticals received EU approval for DAYBU to treat Rett syndrome. Shares are declining despite this development, reflecting unusual volatility during Friday's session.

27 de ago. de 2026, 23:41 UTC

ACADIA Pharmaceuticals shares are trading lower in after-market hours, despite being above the 20-day moving average and near the upper end of its trading range.

26 de ago. de 2026, 20:08 UTC

ACADIA Pharmaceuticals is trading lower amid a weaker market following inflation data that may influence future Federal Reserve policy decisions.

25 de ago. de 2026, 20:07 UTC

Analysts' upgrades boost ACADIA Pharmaceuticals, with Deutsche Bank raising its price target to $38 and Citigroup to $40 following DAYBUE's EU approval.

24 de ago. de 2026, 20:06 UTC

ACADIA Pharmaceuticals received European Commission approval for DAYBU, the first treatment for Rett syndrome in the EU. Shares are advancing during Monday's session.

21 de ago. de 2026, 19:56 UTC

ACADIA Pharmaceuticals shares are higher, recovering from an early dip. The move aligns with broader market trends following a surge in Bitcoin prices.

20 de ago. de 2026, 20:01 UTC

ACADIA Pharmaceuticals shares are lower amid a broader decline in biotechnology stocks, with unusual volatility noted today and cumulative returns down since Wednesday.

19 de ago. de 2026, 19:46 UTC

ACADIA Pharmaceuticals is trading higher, reflecting positive sentiment in the biotechnology sector amid declining bond yields and increased liquidity, despite a recent pullback.

18 de ago. de 2026, 20:02 UTC

BMO maintained an Outperform rating on ACADIA Pharmaceuticals with a $36 price target, contributing to positive market sentiment and advancing shares today.

17 de ago. de 2026, 23:06 UTC

ACADIA Pharmaceuticals shares are trading higher in after-market hours, maintaining a gain while above their 20-day moving average and near a one-month high.

13 de ago. de 2026, 20:01 UTC

ACADIA Pharmaceuticals Inc shares are lower today, continuing a decline from Wednesday's close. No specific news was identified to explain the movement.

12 de ago. de 2026, 19:56 UTC

Needham maintained its Buy rating on ACADIA Pharmaceuticals and raised the price target to $41. Shares are trading higher since Tuesday's close.

11 de ago. de 2026, 19:36 UTC

ACADIA Pharmaceuticals remains near unchanged amid broader market sentiment influenced by geopolitical tensions and upcoming U.S. inflation reports affecting interest rate policy.

7 de ago. de 2026, 20:06 UTC

ACADIA Pharmaceuticals Inc shares are advancing, maintaining a strong position above the 20-day moving average and near the upper end of their one-month range.

6 de ago. de 2026, 23:41 UTC

ACADIA Pharmaceuticals shares are higher in after-market trading, reflecting strong performance above its 20-day moving average and nearing the upper end of its one-month range.

5 de ago. de 2026, 20:02 UTC

ACADIA Pharmaceuticals shares rise following strong Q2 results and positive analyst ratings, with revenue guidance increased to $1.24 billion to $1.30 billion.

4 de ago. de 2026, 23:01 UTC

Acadia Pharmaceuticals shares are higher after reporting strong Q2 results, with GAAP net sales of DAYBUE reaching $125 million and raising full-year revenue guidance.

3 de ago. de 2026, 21:01 UTC

ACADIA Pharmaceuticals Inc shares are lower in after-market trading, continuing a trend of three consecutive sessions finishing lower without any specific news identified.

31 de jul. de 2026, 20:03 UTC

ACADIA Pharmaceuticals shares are lower today, continuing a decline since Thursday's close. Rising Treasury yields and crude oil prices contribute to inflation concerns.

30 de jul. de 2026, 19:58 UTC

ACADIA Pharmaceuticals shares are higher, reflecting a broader recovery in tech stocks amid improving market sentiment and bargain hunting after recent sell-offs.

29 de jul. de 2026, 20:41 UTC

ACADIA Pharmaceuticals shares are lower in after-market trading amid a broader market decline linked to rising crude oil prices and geopolitical tensions.

28 de jul. de 2026, 20:06 UTC

ACADIA Pharmaceuticals is rising amid strong performance in the Biotechnology sector. The stock is nearing the upper end of its one-month range.

27 de jul. de 2026, 20:01 UTC

ACADIA Pharmaceuticals Inc. shares are higher today, continuing an upward trend since Friday's close, despite no specific news driving the price movement.

24 de jul. de 2026, 19:56 UTC

ACADIA Pharmaceuticals shares are higher since Thursday's close, despite a dip earlier in the session. The stock remains below its 20-day moving average.

23 de jul. de 2026, 10:06 UTC

ACADIA Pharmaceuticals is trading higher in pre-market hours, recovering from an earlier dip. The stock remains below its 20-day moving average.

22 de jul. de 2026, 22:16 UTC

ACADIA Pharmaceuticals shares are lower in after-market trading, with unusual activity noted. Broader market concerns may be influencing investor sentiment.

21 de jul. de 2026, 23:16 UTC

ACADIA Pharmaceuticals Inc. shares traded roughly flat in after-market hours, remaining near the upper end of their one-month trading range.

20 de jul. de 2026, 19:56 UTC

Acadia Pharmaceuticals received Fast Track designation for remlifanserin, but shares are lower today, continuing a trend of declines over the past three sessions.